Neoadjuvant chemoradiation therapy and pathological complete response in rectal cancer

Gastroenterology Report

Volumn 3, Issue 4, 2015, Pages 277-288

  Ferrari, Linda ^a   Fichera, Alessandro ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Neoadjuvant chemoradiation therapy; Pathological complete response; Rectal cancer

Indexed keywords

EID: 84988381848     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gov039     Document Type: Review

References (88)

1. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-72.
2. Krook JE, Moertel CG, Gunderson LL et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
3. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
4. Heald RJ and Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-82.
5. Arbman G, Nilsson E, Hallböök O et al. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 1996;83:375-9.
6. Kapiteijn E, Putter H, van de Velde CJCo-operative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002;89:1142-9.
7. Sauer R, Becker H, Hohenberger W et al. German Rectal Cancer Study Group. Pre-operative vs. post-operative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
8. Sauer R, Liersch T, Merkel S et al. Pre-operative vs. post-operative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926-33.
9. MaasM, Nelemans PJ, Valentini V et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: A pooled analysis of individual patient data. Lancet Oncol 2010;11:835-44.
10. Garcia-Aguilar J, Shi Q, Thomas CR Jr et al. A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: Preliminary results of the ACOSOG Z6041 trial. Ann Surg Oncol 2012;19:384-91.
11. Habr-Gama A, Perez RO, NadalinWet al. Operative vs. nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long-term results. Ann Surg 2004;240:711-18.
12. Habr-Gama A, Perez RO, Proscurshim I et al. Patterns of failure and survival for non-operative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg 2006;10:1319-29.
13. Smith JD, Ruby JA, Goodman KA et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 2012;256:965-72.
14. Maas M, Beets-Tan RG, Lambregts DM et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 2011;29:4633-40.
15. Fernandez-Martos C, Brown G, Estevan R et al. Pre-operative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: The GEMCAD 0801 Phase II Multicenter Trial. Oncologist 2014;19:1042-3.
16. Schrag D, Weiser MR, Goodman KA et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: A pilot trial. J Clin Oncol 2014;32:513-18.
17. Schrag D. Evolving role of neoadjuvant therapy in rectal cancer. Curr Treat Options Oncol 2013;14:350-64.
18. Smith JJ and Garcia-Aguilar J. Advances and Challenges in Treatment of Locally Advanced Rectal Cancer. J Clin Oncol 2015;133:1797-808.
19. Samdani T and Garcia-Aguilar J. Imaging in rectal cancer: Magnetic resonance imaging vs. endorectal ultrasonography. Surg Oncol Clin N Am 2014;23:59-77.
20. Brown G, Davies S, Williams GT et al. Effectiveness of preoperative staging in rectal cancer: Digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer 2004;91:23-9.
21. Al-Sukhni E, Milot L, Fruitman M et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: A systematic review and metaanalysis. Ann Surg Oncol 2012;19:2212-23.
22. MERCURY Study Group. Diagnostic accuracy of pre-operative magnetic resonance imaging in predicting curative resection of rectal cancer: Prospective observational study. BMJ 2006;333:779.
23. Taylor FG, Quirke P, Heald RJ et al. Magnetic Resonance Imaging in Rectal Cancer European Equivalence Study Study Group. Pre-operative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014;32:34-43.
24. Taylor FG, Quirke P, Heald RJ et al. MERCURY study group. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: A prospective, multicenter, European study. Ann Surg 2011;253:711-19.
25. Battersby NJ, How P, Moran B et al. MERCURY II Study Group. Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study. Ann Surg 2015 Mar27. [Epub ahead of print]
26. Benson AB, Venook AP, Saltz L. NCCN Guidelines version 2.2015 (rectal cancer), 2015. www.nccn.org.
27. Smith N and Brown G. Pre-operative staging of rectal cancer. Acta Oncol 2008;47:20-31.
28. Blomqvist L and Glimelius B. The 'good', the 'bad', and the 'ugly' rectal cancers. Acta Oncol 2008;47:5-8.
29. Glynne-Jones R, Tan D, Goh V. Pelvic MRI for guiding treatment decisions in rectal cancer. Oncology (Williston Park) 2014;28:667-77.
30. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Dutch Colorectal Cancer Group. Pre-operative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
31. Bosset JF, Calais G, Mineur L et al. Enhanced tumoricidal effect of chemotherapy with pre-operative radiotherapy for rectal cancer: Preliminary results: EORTC 22921. J Clin Oncol 2005;23:5620-7.
32. Bossett JF, Collete L, Calais G et al. EORTC Radiotherapy Group Trial 22921. Chemotherapy with pre-operative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
33. Gerard JP, Conroy T, Bonnetain F et al. Pre-operative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: Results of FFCD9203. J Clin Oncol 2006;24:4620-5.
34. Peeters KC, van de Velde CJ, Leer JW et al. Late side effects of short-course pre-operative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients: A Dutch colorectal cancer group study. J Clin Oncol 2005;23:6199-206.
35. Roh MS, Colangelo LH, O'ConnellMJ et al. Pre-operative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009;27:5124-30.
36. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Longterm results of a randomized trial comparing pre-operative short-course radiotherapy with pre-operative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-23.
37. Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy vs. long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30:3827-33.
38. Roh MS, Yothers GA, O'Connell MJ et al. The impact of capecitabine and oxaliplatin in the pre-operative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011; 29 Suppl:abstr 3503.
39. Gérard JP, Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/ 0405-Prodige 2. J Clin Oncol 2010;28:1638-44.
40. Park IJ, You YN, Agarwal A et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol 2012;30:1770-6.
41. Tulchinsky H, Shmueli E, Figer A et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathological complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008;15:2661-7.
42. Kalady MF, de Campos-Lobato LF, Stocchi L et al. Predictive factors of pathological complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009;250:582-9.
43. Moore HG, Gittleman AE, Minsky BD et al. Rate of pathological complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004;47:279-86.
44. Zeng WG, Zhou ZX, Liang JW et al. Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncological outcome. J Surg Oncol 2014;110:463-7.
45. Habr-Gama A, Perez RO, Sabbaga J et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: Results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009;52:1927-34.
46. Habr-Gama A, Sabbaga J, Gama-Rodrigues J et al. 'watch and wait' approach following extended neoadjuvant chemoradiation for distal rectal cancer: Are we getting closer to anal cancer management? Dis Colon Rectum 2013;56:1109-17.
47. Myerson RJ, Tan B, Hunt S et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys 2014;88:829-36.
48. Garcia-Aguilar J, Smith DD, Avila K et al. Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: Preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011;254:97-102.
49. Garcia-Aguilar J, Marcet J, Coutsoftsides T et al. Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer tretment with TME. J Clin Oncol 2011;29 Suppl: Abstr 3514.
50. Benson AB 3rd, Bekaii-Saab T, Chan E et al. Rectal cancer. J Natl Compr Canc Netw 2012;10:1528-64.
51. Bosset JF, Calais G, Mineur L et al. EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014;15:184-90.
52. Breugom AJ, Swets M, Bosset JF et al. Adjuvant chemotherapy after pre-operative (chemo)radiotherapy and surgery for patients with rectal cancer: A systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:200-7.
53. Hayden DM, Pinzon MC, Francescatti AB et al. Hospital readmission for fluid and electrolyte abnormalities following ileostomy construction: Preventable or unpredictable? J Gastrointest Surg 2013;17:298-303.
54. Khrizman P, Niland JC, ter Veer A et al. Post-operative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: A national comprehensive cancer network analysis. J Clin Oncol 2013;31:30-8.
55. Biagi JJ, Raphael MJ, Mackillop WJ et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis. JAMA 2011;305:2335-42.
56. Chau I, Brown G, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668-74.
57. Chua YJ, Barbachano Y, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: A phase 2 trial. Lancet Oncol 2010;11:241-8.
58. Fernández-Martos C, Pericay C, Aparicio J et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010;28:859-65.
59. Schou JV, Larsen FO, Rasch L et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol 2012;23:2627-33.
60. Maréchal R, Vos B, Polus M et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: A randomized multicentric phase II study. Ann Oncol 2012;23:1525-30.
61. Cercek A, Goodman KA, Hajj C et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw 2014;12:513-19.
62. Capirci C, Valentini V, Cionini L et al. Prognostic value of pathological complete response after neoadjuvant therapy in locally advanced rectal cancer: Long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008;72:99-107.
63. Gunderson LL, Sargent DJ, Tepper JE et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: A pooled analysis. J Clin Oncol 2004;22:1785-96.
64. Gunderson LL, Callister M, Marschke R et al. Stratification of rectal cancer stage for selection of post-operative chemoradiotherapy: Current status. Gastrointest Cancer Res 2008; 2:25-33.
65. Willett CG, Badizadegan K, Ancukiewicz M et al. Prognostic factors in stage T3N0 rectal cancer: Do all patients require post-operative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999;42:167-73.
66. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B; Swedish Rectal Cancer Trial Group. Adverse effects of pre-operative radiation therapy for rectal cancer: Long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005;23:8697-705.
67. Joye I and Haustermans K. Early and late toxicity of radiotherapy for rectal cancer. Recent Results Cancer Res 2014;203: 189-201.
68. Smith FM, Rao C, Oliva Perez R et al. Avoiding radical surgery improves early survival in elderly patients with rectal cancer, demonstrating complete clinical response after neoadjuvant therapy: Results of a decision-analytic model. Dis Colon Rectum 2015;58:159-71.
69. Rutten HJ, den Dulk M, Lemmens VE et al. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 2008;9:494-501.
70. Habr-Gama A, São Julião GP, Perez RO. Nonoperative management of rectal cancer: Identifying the ideal patients. Hematol Oncol Clin North Am 2015;29:135-51.
71. Habr-Gama A, Perez RO, Wynn G et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: Characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010;53:1692-8.
72. Duldulao MP, Lee W, Streja L et al. Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum 2013;56:142-9.
73. Habr-Gama A, Gama-Rodrigues J, São Julião GP et al. Local recurrence after complete clinical response and 'watch and wait' in rectal cancer after neoadjuvant chemoradiation: Impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 2014;88:822-8.
74. Habr-Gama A, São Julião GP, Perez RO. Nonoperative management of rectal cancer: Identifying the ideal patients. Hematol Oncol Clin North Am 2015;29:135-51.
75. Murad-Regadas SM, Regadas FS, Rodrigues LV et al. Role of three-dimensional anorectal ultrasonography in the assessment of rectal cancer after neoadjuvant chemotherapy. Preliminary results. Surg Endosc 2009;23:1286-91.
76. Murad-Regadas SM, Regadas FS, Rodrigues LV et al. Criteria for three-dimensional anorectal ultrasound assessment of response to chemoradiotherapy in rectal cancer patients. Colorectal Dis 2011;13:1344-50.
77. Van der Paardt MP, Zagers MB, Beets-Tan RG et al. Patients who undergo pre-operative chemoradiotherapy for locally advanced rectal cancer re-staged by using diagnostic MR imaging: A systematic review and meta-analysis. Radiology 2013;269:101-12.
78. Hötker AM, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI of rectal cancer in the assessment of response to therapy: A systematic review. Dis Colon Rectum 2014;57:790-9.
79. Song I, Kim SH, Lee SJ et al. Value of diffusion-weighted imaging in the detection of viable tumor after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: Comparison with T2 weighted and PET/CT imaging. Br J Radiol 2012;85:577-86.
80. Lambrecht M, Vandecaveye V, De Keyzer F et al. Value od diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: Preliminary results. Int J Radiol Oncol Biol Phys 2012;82:863-70.
81. Lambregts DM, Vandecaveye V, Barbaro B et al. Diffusionweighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: A multicenter study. Ann Surg Oncol 2011;18:2224-31.
82. Lim JS, Kim D, Baek SE et al. Perfusion MRI for the prediction of treatment response after pre-operative chemoradiotherapy in locally advanced rectal cancer. Eur J Radiol 2005;53:514-19.
83. Gollub MJ, Gultekin DH, Akin O et al. Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer. Eur Radiol 2012;22:821-31.
84. Lambregts DM, Beets GL, Maas M et al. Accuracy of gadofosveset-enhanced MRI for nodal staging and re-staging in rectal cancer. Ann Surg 2011;253:539-45.
85. Lambregts DM, Heijnen LA, Maas M et al. Gadofosveset-enhanced MRI fr the assessment for rectal cancer lymph nodes: Predictive criteria. Abdomin Imaging 2013;38:720-7.
86. Perez RO, Habr-Gama A, Gama-Rodrigues J et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: Long-term results of a prospective trial (National Clinical Trial 00254683). Cancer 2012;118:3501-11.
87. Guillem JG, Ruby JA, Leibold T et al. Neither FDG-PET nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: A prospective study. Ann Surg 2013;258:289-95.
88. Kleiman A, Al-Khamis A, Farsi A et al. Normalization of CEA Levels Post-Neoadjuvant Therapy is a Strong Predictor of Pathological Complete Response in Rectal Cancer. J Gastrointest Surg 2015;19:1106-12.